Recent submissions
Now showing items 21-40 of 5047
-
Targeting radioresistance and replication fork stability in prostate cancer.
(AMER SOC CLINICAL INVESTIGATION INC, 2022-05-09)The bromodomain and extraterminal (BET) family of chromatin reader proteins bind to acetylated histones and regulate gene expression. The development of BET inhibitors (BETi) has expanded our knowledge of BET protein ... -
Resistance to DNA repair inhibitors in cancer.
(WILEY, 2022-05-14)The DNA damage response (DDR) represents a complex network of proteins which detect and repair DNA damage, thereby maintaining the integrity of the genome and preventing the transmission of mutations and rearranged chromosomes ... -
Refining colorectal cancer classification and clinical stratification through a single-cell atlas.
(BMC, 2022-05-11)BACKGROUND: Colorectal cancer (CRC) consensus molecular subtypes (CMS) have different immunological, stromal cell, and clinicopathological characteristics. Single-cell characterization of CMS subtype tumor microenvironments ... -
Prostate Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer.
(American Association for Cancer Research (AACR), 2022-05-12)PURPOSE: Prostate specific membrane antigen (PSMA) targeting therapies such as Lutetium-177 (177Lu)-PSMA-617 are impacting outcomes from metastatic castration-resistant prostate cancer (mCRPC). However, a significant subset ... -
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
(ELSEVIER, 2022-05-01)OBJECTIVES: To assess health-related quality of life (HRQoL) with first-line pembrolizumab, pembrolizumab-chemotherapy, or cetuximab-chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) ... -
Infertility and risk of breast cancer in men: a national case-control study in England and Wales.
(BMC, 2022-05-17)PURPOSE: Breast cancer is uncommon in men and its aetiology is largely unknown, reflecting the limited size of studies thus far conducted. In general, number of children fathered has been found a risk factor inconsistently, ... -
Germline MBD4 deficiency causes a multi-tumor predisposition syndrome.
(Elsevier BV, 2022-05-05)We report an autosomal recessive, multi-organ tumor predisposition syndrome, caused by bi-allelic loss-of-function germline variants in the base excision repair (BER) gene MBD4. We identified five individuals with bi-allelic ... -
Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
(Elsevier BV, 2022-05-13)BACKGROUND: BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer (MIBC), demonstrated improvement in locoregional control by adding fluorouracil and mitomycin C to radiotherapy ... -
A road map for designing phase I clinical trials of radiotherapy-novel agent combinations.
(American Association for Cancer Research (AACR), 2022-05-12)Radiotherapy has proven efficacy in a wide range of cancers. There is growing interest in evaluating radiotherapy-novel agent combinations, and a drive to initiate this earlier in clinical development of the novel agent, ... -
Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology.
(Wiley, 2022-07-01)BACKGROUND: Metastatic epithelioid sarcoma (EPS) remains a largely unmet clinical need in children, adolescents and young adults despite the advent of EZH2 inhibitor tazemetostat. METHODS: In order to realise consistently ... -
An exploration of mechanisms and effects of oncogenic KRAS on the tumour immune microenvironment
(Institute of Cancer Research (University Of London), 2022-07-06)Oncogenic KRAS influences several cancer hallmarks including autonomy from growth promoting signals, enhanced cell survival and altered tumour metabolism. Beyond these, it is now established that oncogenic KRAS can polarise ... -
Selective autophagy receptors in pancreatic ductal adenocarcinoma
(Institute of Cancer Research (University Of London), 2022-07-06)Pancreatic cancer accounted for 2.5% of all new cancers diagnosed worldwide in 2018, but remains disproportionally one of the most lethal cancers. Therefore, the development and validation of novel biomarkers (BMs), for ... -
Characterisation of RELA dynamics in pancreatic ductal adenocarcinoma
(Institute of Cancer Research (University Of London), 2022-07-06)The NF-kB transcription factor RELA is a master regulator of the immune response and cell survival. Numerous studies have determined the parameters and configuration of single cell RELA translocation dynamics, with various ... -
Hyperthermic intraperitoneal chemotherapy (HIPEC) as another treatment modality for desmoplastic round cell tumour patients: first paediatric experience from UK.
(BMJ PUBLISHING GROUP, 2021-01-28)We present the first young paediatric patient with desmoplastic small round cell tumour (DSRCT) treated in UK with hyperthermic intraperitoneal chemotherapy (HIPEC). A 7-year-old girl was diagnosed with abdominal DSRCT ... -
Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study.
(Elsevier BV, 2022-06-08)BACKGROUND: Adolescent and young adult patients with rhabdomyosarcoma often have poorer outcomes than do children. We aimed to compare the findings of adolescent and young adult patients with children enrolled in two ... -
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study.
(MDPI AG, 2022-04-30)We aimed to overcome intratumoral heterogeneity in clear cell renal cell carcinoma (clearRCC). One hundred cases of clearRCC were sampled. First, usual standard sampling was applied (1 block/cm of tumor); second, the whole ... -
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
(LIPPINCOTT WILLIAMS & WILKINS, 2022-05-01)PURPOSE: Patients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction, and increased monitoring ... -
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
(ELSEVIER IRELAND LTD, 2022-05-01)OBJECTIVE: In CheckMate 743 (NCT02899299), nivolumab + ipilimumab significantly prolonged overall survival in patients with unresectable malignant pleural mesothelioma (MPM). We present patient-reported outcomes (PROs). ... -
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.
(AMER MEDICAL ASSOC, 2022-05-01)Importance: Angiosarcoma is a rare sarcoma subtype with a poor outcome. Carotuximab plus pazopanib produced a median progression-free survival (PFS) of 7.8 months in pazopanib-naive patients with chemotherapy-refractory ... -
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE).
(Elsevier BV, 2022-05-08)BACKGROUND: ESMO COVID-19 and CAncer REgistry (ESMO-CoCARE) is an international collaborative registry-based, cohort study gathering real-world data from Europe, Asia/Oceania and Africa on the natural history, management ...
